Spadaccino Federica, Gigante Margherita, Netti Giuseppe Stefano, Rocchetti Maria Teresa, Franzin Rossana, Gesualdo Loreto, Castellano Giuseppe, Stallone Giovanni, Ranieri Elena
Clinical Pathology Unit, Center of Molecular Medicine, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy.
Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy.
Pharmaceuticals (Basel). 2021 Apr 2;14(4):322. doi: 10.3390/ph14040322.
The analysis of microRNA (miRNAs), small, non-coding endogenous RNA, plays a crucial role in oncology. These short regulatory sequences, acting on thousands of messenger RNAs (mRNAs), modulate gene expression at the transcriptional and post-transcriptional level leading to translational repression or degradation of target molecules. Although their function is required for several physiological processes, such as proliferation, apoptosis and cell differentiation, miRNAs are also responsible for development and/or progression of several cancers, since they may interact with classical tumor pathways. In this review, we highlight recent advances in deregulated miRNAs in cancer focusing on renal cell carcinoma (RCC) and provide an overview of the potential use of miRNA in their clinical settings, such as diagnostic and prognostic markers.
微小RNA(miRNA)是一类短小的非编码内源性RNA,对其进行分析在肿瘤学中起着至关重要的作用。这些短调控序列作用于数千种信使RNA(mRNA),在转录和转录后水平调节基因表达,导致靶分子的翻译抑制或降解。尽管miRNA的功能在多种生理过程中是必需的,如增殖、凋亡和细胞分化,但由于它们可能与经典肿瘤通路相互作用,因此也与多种癌症的发生和/或进展有关。在本综述中,我们重点介绍了肾细胞癌(RCC)中失调的miRNA的最新进展,并概述了miRNA在临床环境中的潜在用途,如诊断和预后标志物。